Lentaigne Claire, Freson Kathleen, Laffan Michael A, Turro Ernest, Ouwehand Willem H
Centre for Haematology, Imperial College Academic Health Sciences Centre, Imperial College London, London, United Kingdom; Imperial College Healthcare National Health Service Trust, London, United Kingdom;
Department of Cardiovascular Sciences, Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium;
Blood. 2016 Jun 9;127(23):2814-23. doi: 10.1182/blood-2016-03-378588. Epub 2016 Apr 19.
Variations in platelet number, volume, and function are largely genetically controlled, and many loci associated with platelet traits have been identified by genome-wide association studies (GWASs).(1) The genome also contains a large number of rare variants, of which a tiny fraction underlies the inherited diseases of humans. Research over the last 3 decades has led to the discovery of 51 genes harboring variants responsible for inherited platelet disorders (IPDs). However, the majority of patients with an IPD still do not receive a molecular diagnosis. Alongside the scientific interest, molecular or genetic diagnosis is important for patients. There is increasing recognition that a number of IPDs are associated with severe pathologies, including an increased risk of malignancy, and a definitive diagnosis can inform prognosis and care. In this review, we give an overview of these disorders grouped according to their effect on platelet biology and their clinical characteristics. We also discuss the challenge of identifying candidate genes and causal variants therein, how IPDs have been historically diagnosed, and how this is changing with the introduction of high-throughput sequencing. Finally, we describe how integration of large genomic, epigenomic, and phenotypic datasets, including whole genome sequencing data, GWASs, epigenomic profiling, protein-protein interaction networks, and standardized clinical phenotype coding, will drive the discovery of novel mechanisms of disease in the near future to improve patient diagnosis and management.
血小板数量、体积和功能的变化在很大程度上受基因控制,全基因组关联研究(GWAS)已鉴定出许多与血小板性状相关的基因座。(1)基因组中还包含大量罕见变异,其中极小一部分是人类遗传性疾病的基础。过去30年的研究发现了51个携带有导致遗传性血小板疾病(IPD)变异的基因。然而,大多数IPD患者仍未得到分子诊断。除了科学研究兴趣外,分子或基因诊断对患者也很重要。人们越来越认识到,许多IPD与严重病理状况相关,包括恶性肿瘤风险增加,明确的诊断可为预后和治疗提供依据。在本综述中,我们根据这些疾病对血小板生物学的影响及其临床特征对其进行了概述。我们还讨论了识别候选基因及其因果变异的挑战、IPD的历史诊断方法以及随着高通量测序的引入这一情况如何变化。最后,我们描述了大型基因组、表观基因组和表型数据集(包括全基因组测序数据、GWAS、表观基因组分析、蛋白质 - 蛋白质相互作用网络和标准化临床表型编码)的整合将如何在不久的将来推动疾病新机制的发现,以改善患者的诊断和管理。